THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTES AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.
THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Accretion® Nutraveda Limited

(Scan this QR code to view the Prospectus)

ACCRETION NUTRAVEDA LIMITED

CIN: U24290GJ2021PLC121216

Our Company was incorporated on March 16, 2021 as 'Accretion Nutraveda Private Limited' which further converted on May 02, 2025 as 'Accretion Nutraveda Limited', a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 02, 2025 issued by the Registrar of Companies, Central Processing Centre.

Registered Office: 27 Xcelan Industrial Park-1, Vasna-Chacharwadi, Ta- Sanand, Ahmedabad, Gujarat, India, 382213
Telephone No: 91 – 99043 66177 | **Website:** https://accretionnutraveda.com/ | **E-Mail:** compliance@accretionnutraveda.com
Company Secretary and Compliance Officer: Ms. Payal Hareshbhai Kotadiya.

PROMOTERS OF OUR COMPANY: MR. MAYUR POPATLAL SOJITRA, MR. ANKURKUMAR SHANTILAL PATEL, MR. PARASKUMAR VINUBHAI PARMAR, MR. HARDIK MUKUNDBHAI PRAJAPATI, MR. HARSHAD NANUBHAI RATHOD & MR. VIVEK ASHOK KUMAR PATEL

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF THE BSE LIMITED ("BSE SME")."

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

Our Company is in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. We are a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. We offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science.

For further details, please see chapter titled ***"Our Business"*** beginning on page 186 of the Prospectus.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 19,20,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF ACCRETION NUTRAVEDA LIMITED ("NUTRAVEDA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 129/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 119/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 2476.80 LAKHS ("THE ISSUE"), OF WHICH 96,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 129/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 119/- PER EQUITY SHARE AGGREGATING TO ₹ 123.84 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 18,24,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 129/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 119/- PER EQUITY SHARE AGGREGATING TO ₹ 2352.96 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.52% AND 25.19%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10/- EACH AND ISSUE PRICE IS ₹ 129 EACH.
THE ISSUE PRICE IS 12.90 TIMES OF THE FACE VALUE OF THE EQUITY SHARE.

ANCHOR INVESTOR ISSUE PRICE: ₹ 129 PER EQUITY SHARE.
THE ISSUE PRICE IS 12.90 TIMES OF THE FACE VALUE.

BID/ISSUE PROGRAMME

ANCHOR PORTION BIDDING DATE WAS: TUESDAY, JANUARY 27, 2026
BID/ISSUE OPENED ON: WEDNESDAY, JANUARY 28, 2026
BID/OFFER CLOSED ON: FRIDAY, JANUARY 30, 2026

RISKS TO INVESTORS

1. **Risk to Investors: Summary description of key risk factors based on materiality:**
a) Our manufacturing operations are subject to risks, including equipment failure, accidents, and natural disasters, which could disrupt production.
b) There are certain discrepancies and non-compliances noticed in some of our corporate records relating to forms filed with the Registrar of Companies, taxation authorities and other public authorities. Any penalty or action taken by any regulatory authorities in future for non- compliance with provisions of all applicable law could impact on the financial position of the Company to that extent.
c) Our Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
d) We have historically derived, and may continue to derive, a significant portion of our supply from top 10 Suppliers.
e) Too much Geographical concentration of our Business on specific location can impact our business.

2. **Details of outlaw ratios of the company and its peer group for the latest full financial year:**

Sr. No.	Name of the company	Face Value (₹ Per Share)	EPS (in ₹)	P/E Ratio	RoNW (%)	Net Asset value per share (₹)
1	Accretion Nutraveda Limited*	10	4.73	27.27	56.50%	16.24
Peer group						
2	Walpar Nutritions Limited	10	1.06	3.20	6.24%	17.05
3	Influx Healthtech Limited	10	4.81	46.99	11.10%	38.98

*Source: The Company's Financial Figures are based on restated standalone audited financial statements for the period ended on September 30, 2025 unless provided otherwise. With respect to industry peers, all the financial information mentioned above is taken for the period as on September 30, 2025 (Half Yearly Unaudited result) available on the website of NSE dated December 22, 2025 to compute the corresponding financial ratios.
** Calculation done considering the floor price of Rs. 122 and cap price of ₹ 129.
Notes for peer group:
a) P/E ratios for the above peer company is based on closing market prices of equity shares on NSE dated December 22, 2025 divided by the Basic and Diluted EPS as at September 30, 2025.
b) Basic and Diluted EPS refers to the Basic and Diluted EPS sourced from the available financial data as on September 30, 2025 of the listed peer company.
c) Return on Net Worth (%) for listed peer company has been computed based on the Net Profit After Tax for the period ended September 30, 2025 divided by Total Equity as on September 30, 2025.
d) NAV per share for listed peer company is computed as the net worth as on September 30, 2025 divided by the outstanding number of equity shares as on September 30, 2025.

3. **Weighted average return on net worth for the last 3 FYs, and return on net worth for any interim period for the issuer company:**

Particulars	RONW%	Weight
Year ended 31st March, 2023	106.66%	1
Year ended 31st March, 2024	75.75%	2
Year ended 31st March, 2025	48.85%	3
Weighted Average	**67.45%**	
For the Six months ended September 30, 2025	56.50%*	

*Annualized

Notes:
a) The RoNW has been computed by dividing restated net profit after tax with restated Net worth as at the end of the year/period.
b) Net Worth means the aggregate value of the Paid-up share capital and all reserves created out of the profits and securities premium account reduced by miscellaneous expenditure and the debit of Profit and Loss Account.
c) Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights

4. **Disclosures as per clause (9)(K)(d) of Part A to Schedule VI:**
a) **The price per share of our Company based on the primary/ new issue of shares (equity/ convertible securities) excluding shares issued under ESOP/ ESOS and issuance of bonus shares, during the 18 months preceding the date of this Red Herring Prospectus, where such issuance is equal to or more that 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Issuance").**

Date of Allotment	No. of Equity Shares allotted*	Face value (₹)	Issue Price (₹)	(Issue price Adjusted for Bonus Issue) *	Nature of consideration	Nature of Allotment	Consideration (₹ In Lac) *
28/03/2025	9,00,000	10	130	13	Cash	Right Issue	117.00
28/03/2025	3,70,000	10	130	13	Cash	Right Issue	48.10
06/09/2025	4,50,000	10	130	13	Cash	Right Issue	58.50

*The Company has allotted 47,88,000 Equity shares through Bonus Issue on September 10, 2025. This transaction has been ignored for the purpose of this clause as the transaction is of nature of Bonus Allotment and does not fall under this clause.

b) **The price per share of our Company based on the secondary sale/ acquisition of shares (equity shares), where the promoters, members of the promoter group or shareholder(s) selling shares through offer for sale in IPO or shareholder(s) having the right to nominate director(s) in the Board of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Red Herring Prospectus/ Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days:**

Name of Transferee	Name of Transferor	Date of Transfer	Number of shares*	Transfer price per Equity Share (in ₹) *
Paraskumar Vinubhai Parmar	Hardik Mukundbhai Prajapati	28.11.2024	1,80,000	3
Paraskumar Vinubhai Parmar	Harshad Nanubhai Rathod	28.11.2024	1,80,000	3
Paraskumar Vinubhai Parmar	Mayur Popatlal Sojitra	28.11.2024	1,80,000	3
Paraskumar Vinubhai Parmar	Vivek Ashok Kumar Patel	28.11.2024	1,80,000	3
Vaishali Hardik Prajapati	Hardik Mukundbhai Prajapati	28.11.2024	1,00,000	3
Pooja Harshad Rathod	Harshad Nanubhai Rathod	28.11.2024	1,00,000	3
Sheeta Sojitra	Mayur Popatlal Sojitra	28.11.2024	1,00,000	3
Ankita Vivek Patel	Vivek Ashok Kumar Patel	28.11.2024	1,00,000	3

*The Company has allotted 47,88,000 Equity shares through Bonus Issue on September 10, 2025. This transaction has been ignored for the purpose of this clause as the transaction is of nature of Bonus Allotment and does not fall under this clause.

PROPOSED LIST PROPOSED LISTING: FEBRUARY 04, 2026*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, states that not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investors shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) (Amendment) Regulations, 2025. All Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "***Issue Procedure***" beginning on page 416 of Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to BSE LIMITED ("**BSE SME**"). For the purpose of this Issue, the designated Stock Exchange will be the BSE LIMITED. The trading is proposed to be commenced on or before February 4, 2026*
*Subject to the receipt of listing and trading approval from the ("BSE SME").

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on Tuesday, January 27, 2026. The Company received 2 Anchor Investors applications for 624,000 Equity Shares. The Anchor Investor Allocation price was finalized ₹ 129/- per Equity Share. A total of 5,44,000 Equity Shares were allocated under the Anchor Investor Portion Aggregating to ₹ 7,01,76,000/-

The Issue (excluding Anchor Investors Portion) received 817 Applications for 24,70,000 Equity Shares (after considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 1.82 times subscription (excluding reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor investors Portion):

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	Spilled over from QIB MF	Equity Shares Allocated*	No. of times Subscribed	Amount (₹)
1.	Individual Investors	705	1,410,000	840,000	0	840,000	2.30	181,020,000.00
2.	Non-Institutional Investors (More than ₹ 0.20 million and upto ₹ 1 million)	62	214,000	92,000	0	92,000	2.33	27,686,000.00
3.	Non-Institutional Investors (above ₹ 1 million)	47	383,000	184,000	0	184,000	2.08	49,497,000.00
4.	Qualified Institutional Bidders (excluding Anchor Investors)	2	367,000	345,000	19,000	364,000	1.06	47,343,000.00
5.	Qualified Institutional Buyers - MF (excluding Anchor Investors)	0	0	19,000	(19,000)	0	0.00	0.00
6.	Market Maker	1	96,000	96,000	0	96,000	1.00	12,384,000.00
	Total	**817**	**2,470,000**	**1,376,000**	**0**	**1,376,000**	**1.80**	**318,580,000.00**

*Spill over from under subscription of QIBMF Category upto Rs. 24.51lacs of 19,000 shares has been re-allocated to QIB OTHER Investor category above ₹ 469.56 lacs category

Final Demand:
A summary of the final demand as per NSE as on the Bid Offer Closing Date at different Bid prices is as under:

Bid Price	No Of Equity Shares	% of Total	Cumulative Share Total	Cumulative % of Total
122	54,000	1.09	54,000	1.09
123	9,000	0.18	63,000	1.27
124		0.00	63,000	1.27
125	15,000	0.30	78,000	1.57
126	2,000	0.04	80,000	1.61
127	4,000	0.08	84,000	1.69

(Continued next page...)

(Continued from previous page...)

128	14,000	0.28	98,000	1.97
129	48,65,000	98.03	49,63,000	100.00
Total	**49,63,000**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited on February 2, 2026.

1) **Allotment to Individual Investors (After Rejections):** The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 129/- per Equity Share, was finalized in consultation with BSE. The category has been subscribed to the extent of 2.17108 times. The total number of Equity Shares Allotted in this category is 6,40,000 Equity to 320 Successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
2,000	695	100.00	13,90,000	100.00	2,000	64 : 139	6,40,000
TOTAL	**695**	**100.00**	**13,90,000**	**100.00**			**6,40,000**

2) **Allotment to Non-Institutional Investors (More than 2 lots & up to ₹ 1,000,000/-) (After Rejections):** The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 129/- per Equity Share, was finalized in consultation with BSE. The category has been subscribed to the extent of 7.32969 times (after rejection). The total number of Equity Shares Allotted in this category is 92,000 Equity Shares to 30 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/ allotted
3000	46	77.97	1,44,000	67.29	3000	23 : 46	69,000
4000	8	13.56	32,000	14.95	3000	1 : 2	12,000
5000	2	3.39	10,000	4.67	3000	1 : 2	3,000
7000	4	6.45	28,000	13.08	3000	1 : 3	6,000
4000 to 7000	-	0.00	-	0.00	1000	2:7	2,000
Total	**62**	**100.00**	**2,14,000**	**100.00**			**92,000**

Note : 1 Additional lot of 1000 shares each has been allocated to all the successful 7 allottees from Categories 4000 to 7000 in the ratio of 2 : 7

3) **Allotment to Non-Institutional Investors (More than ₹ 1,000,000/-) (After Rejections):** The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 129/- per Equity Share, was finalized in consultation with BSE. The category has been subscribed to the extent of 1.95109 times. The total number of Equity Shares Allotted in this category is 1,84,000 Equity Shares to 44 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares Allotted per Applicant	Ration of allottees to applicants	Total No. of shares allocated/ allotted
6000	42	95.45	3,36,000	93.58	4,000	1 : 1	168,000
8000	-	0.00	-	-	1,000	1 : 7	8,000
11000	1	2.27	11,000	3.06	5,000	1 : 1	5,000
12000	1	2.27	12,000	3.34	5,000	1 : 1	5,000
TOTAL	**44**	**100.0**	**3,59,000**	**100.0**			**1,84,000**

Please Note : 1 additional lot of 1000 shares have been allocated in Category 8000 in the ratio of 1:7

4) **Allotment to QIBs excluding Anchor Investors (After Rejections):** Allotment to QIBs, who have bid at the Issue Price of ₹ 129/- per Equity Share or above, has been done on a proportionate basis in consultation with BSE. This category has been subscribed to the extent of 1.00824 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 364,000 Equity Shares, which were allotted to 2 successful Applicants. The details of the Basis of Allotment of the said category are as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares	Ration of allottees to applicants	Total No. of shares allocated/ allotted
1	5,000	1	50.00	5,000	1.36	4,999.13	1:1	5,000
2	3,62,000	1	50.00	3,62,000	98.64	3,59,040.87	1:1	3,59,000
TOTAL	**3,67,000**	**2**	**100.00**	**3,67,000**	**100.00**			**3,64,000**

5) **Allocation to Market Maker:** The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 129/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed 1.00000 times i.e. for 96,000 Equity Shares the total number of shares allotted in this category is 96,000 Equity Share. The details of Allotment of the said category are as under:

Sr. No.	No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares applied in each category	% of Total	No. of Equity Shares	Ration of allottees to applicants	Total No. of shares allocated/ allotted
1	96,000	1	100.00	96,000	100.00	96,000	1:1	96,000
	TOTAL	**1**	**100.00**	**96,000**	**100.00**			**96,000**

6) **Allotment to Anchor Investors (After Technical Rejection):** The Company in consultation with the BRLM has allocated 544,000 Equity Shares to 2 Anchor Investors at the Anchor Investor Issue Price of ₹ 129/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPI/FPC	VC'S	TOTAL
ANCHOR	-	-	-	0	4,66,000	78,000	-	5,44,000

The Board of Directors of our Company at its meeting held on February 2, 2026 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being BSE Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSBs have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before February 2, 2026 and payment to non-Syndicate brokers have been issued on February 3, 2026. In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before February 3, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from BSE Limited and the trading of the Equity Shares is expected to commence on February 4, 2026.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated February 02, 2025 ("Prospectus").

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) at www.in.mpms.mufg.com

All future correspondence in this regards may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodge and payment details at the address of the Registrar given below:

KFintech
KFin Technologies Limited
Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500 032, Telangana | **Tel No.:** +91 40 6716 2222 | **Email Id:** ipo.ipo@kfintech.com
Investor Grievance Email: einward.ris@kfintech.com | **Website:** www.kfintech.com
Contact Person: Mr. M. Murali Krishna | **SEBI Registration No.:** INR000000221 | **CIN:** L72400MH2017PLC444072

On behalf of Board of Directors
FOR, ACCRETION NUTRAVEDA LIMITED
Sd/-
(MAYUR POPATLAL SOJITRA)
Managing Director
DIN: 08108404

Place: Ahmedabad, Gujarat
Date: February 03, 2026

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF ACCRETION NUTRAVEDA LIMITED.

Disclaimer: Accretion Nutraveda Limited, is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make initial public offering of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on February 02, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is expected to be available on the website of the SEBI at www.sebi.gov.in and the website of the Book Running Lead Manager to the Issue at www.pidilitaccapital.com and website of the BSE Limited at www.bseindia.com and website of Issuer Company at https://accretionnutraveda.com/ . Any potential investors should note that investment in Equity Shares involves high degree of risks. For details, investors should refer to and rely on the Red Herring Prospectus, including the section titled "Risk Factors" on page 34 of the Prospectus. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state securities law in United States and may not be offered or sold within the United States (as defined in Regulation S under the Securities Act) or to, or for the account/ benefit of "U. S. Person" (as defined in the Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act.

ACCRETION NUTRAVEDA LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on November 11, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#emerg_offer and is available on the websites of the BRLM at www.finance capital.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the chapter titled "***Risk Factors***" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

Adfactors